FDA Guidance for Industry: ANDAs: Stability Testing of Drug Substances and Products and FDA Q&A
![](/46/pdcnewsitem/03/33/47/cShz3OpboxRqAQQ.png)
The FDA has published “Guidance for Industry, ANDAs: Stability Testing of Drug Substances and Products, Questions and Answers” in May 2014. This guidance contains questions and answers from public comments generated during the drafting of “Guidance for Industry, ANDAs: Stability Testing of Drug Substances and Products” the final document being published in June 2013 for generics. The guideline recommends that ANDAs, and DMFs (Drug Master Files) which support ANDAs, follow ICH stability guidelines Q1A(R2), Q1B, Q1C, Q1D, Q1E. The implementation date of the Q&A is June 20, 2014.
The Q&A covers five topic areas and is intended to clarify stability testing data recommendations for abbreviated new drug applications (ANDAs) found in the short guideline.
◾ The General section mainly addressing timing, amount of data, and number of lots to use for stability studies
◾ The Drug Master File section covers the impact of guideline to DMFs
◾ The Drug Product Manufacturing and Packaging section takes up most of the Q&A and touches on inclusion of secondary packaging in stability studies, batch size and batch definitions, definition of small scale for various dosage forms as well as “small scale” development guidance.
◾ The section on Amendments to Pending ANDA Application states amendments will be held to the standards in place of original submission.
◾ The Stability Studies section includes guidance on the technical aspects of stability studies such as time points, storage, containers and testing.
To view the Guideline Q&A, click here
To view the original Guidance, click here
Related News
-
News Global advancements in the diagnosis and treatment of rare diseases: Rare Disease Day 2024
Rare Diseases Day is celebrated on the 29th February 2024 and represents the plight of rare disease patients to gain diagnosis and access to suitable treatment. -
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance